Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18882261 | 0.81 | MEN1 (0.33) | — | |
| SCHEMBL21938390 | 0.79 | CES2 (0.32) | CES2LPAR1LPAR3TSHR | |
| SCHEMBL21523907 | 0.78 | ALDH1A1 (0.35) | CES2LPAR1LPAR3TSHRSMN1; SMN2 | |
| SCHEMBL21523908 | 0.78 | — | — | |
| SCHEMBL26064066 | 0.77 | CES2 (0.31) | CES2LPAR1LPAR3TSHR | |
| SCHEMBL24943408 | 0.75 | TSHR (0.30) | TSHR | |
| SCHEMBL16144914 | 0.74 | CES2 (0.32) | CES2LPAR1LPAR3TSHR | |
| SCHEMBL5653717 | 0.74 | CES2 (0.32) | CES2LPAR1LPAR3TSHR | |
| SCHEMBL13912058 | 0.73 | — | — | |
| SCHEMBL9630699 | 0.72 | TSHR (0.31) | TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382272-B2 | Methods of making lubiprostone and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2016-07-05 | — | — | US | disclosed |
| US-9382272-B2 | Methods of making lubiprostone and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2016-07-05 | — | — | US | disclosed |
| US-20120065409-A1 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065409-A1 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF | PTGIS, LSS, SQLE | CES2 1201/4885LPAR1 114/4885LPAR3 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.